van de Peppel R J, von dem Borne P A, le Cessie S, de Boer M G J
Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.
Department of Haematology, Leiden University Medical Center, Leiden, The Netherlands.
Bone Marrow Transplant. 2017 Jun;52(6):883-888. doi: 10.1038/bmt.2017.71. Epub 2017 May 15.
Invasive aspergillosis (IA) has been reported to yield high mortality rates. Patients with an unfavourable prognostic haematological disease not only have a higher probability of developing IA but are also more likely to die due to causes directly related to the underlying disease. This complexity of risk mechanisms confounds the causal interpretation of IA occurrence and mortality. Full consideration of the changing patient characteristics over time is necessary to obtain reliable estimates of the correlation of IA with mortality. We studied the effect of IA on mortality in 167 consecutive patients starting with remission-induction therapy for AML or of whom most patients continued to haematopoietic stem cell transplantation (HSCT). No standard antifungal prophylaxis was administered in the period before HSCT. Survival analyses were performed to determine risk estimates of IA for different phases of treatment before and after HSCT. Time-dependent adjustment for confounding variables was performed using Cox proportional hazards models. In 55 of 167 enroled patients, IA was diagnosed. Before HSCT, adjusted hazard ratios and 95% confidence intervals on mortality after the diagnosis of IA were 3.5 (1.7-7.5), 2.0 (0.69-5.9), 2.3 (0.79-6.8) and 0.80 (0.49-1.4) within 30 days, between 30 and 60 days, between 60 and 90 days or more than 90 days, respectively. A similar pattern was observed after HSCT. The occurrence of IA did not significantly influence the decision to follow through with HSCT. The results provide new insights in short- and long-term survival of patients diagnosed with IA. A significantly increased mortality risk was only observed in the first month after diagnosis of IA. No unfavourable association with mortality was observed in the later course of treatment. The occurrence of IA did not affect the probability of attaining HSCT in our population.
侵袭性曲霉病(IA)据报道死亡率很高。患有预后不良血液系统疾病的患者不仅发生IA的可能性更高,而且更有可能因与基础疾病直接相关的原因死亡。这种风险机制的复杂性混淆了IA发生和死亡率的因果解释。为了获得IA与死亡率相关性的可靠估计,有必要充分考虑患者特征随时间的变化。我们研究了IA对167例连续接受急性髓系白血病(AML)缓解诱导治疗的患者死亡率的影响,其中大多数患者继续接受造血干细胞移植(HSCT)。在HSCT前的时期未进行标准抗真菌预防。进行生存分析以确定HSCT前后不同治疗阶段IA的风险估计。使用Cox比例风险模型对混杂变量进行时间依赖性调整。在167例登记患者中,有55例被诊断为IA。在HSCT前,IA诊断后30天内、30至60天之间、60至90天之间或超过90天的调整后风险比及95%置信区间分别为3.5(1.7 - 7.5)、2.0(0.69 - 5.9)、2.3(0.79 - 6.8)和0.80(0.49 - 1.4)。HSCT后观察到类似模式。IA的发生并未显著影响继续进行HSCT的决定。结果为诊断为IA的患者的短期和长期生存提供了新的见解。仅在IA诊断后的第一个月观察到死亡率风险显著增加。在治疗后期未观察到与死亡率的不利关联。在我们的研究人群中,IA的发生并未影响进行HSCT的概率。